Novel Drug (DDT) and Medical Device Development Tools (MDDT) to Help Expedite Creation and Regulatory Approvals of New Therapies for Substance Use Disorders (SUD) (R41/R42, R43/R44 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications proposing research projects, directed towards commercialization, for the development of new drug development tools (DDT) and medical device development tools (MDDT) in the field of substance use disorder (SUD) research. DDTs and MDDTs developed with funds from this FOA are expected to support investigators and medical product developers by facilitating and expediting regulatory approval of new medical products developed for diagnosis, monitoring, and/or treatment of patients with SUD.

Companion FOA: RFA-DA-23-020 , R43/ R44 Small Business Innovation Research Grants (SBIR) - Phase I/ Small Business Innovation Research Grants (SBIR) - Phase II


  • Letter of Intent Due Date(s): October 14, 2022

  • Application Due Date: November 14, 2022

RFA-DA-23-019 Expiration Date November 15, 2022


Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Amount Description

Total funding support (direct costs, indirect costs, fees) may not exceed $320,000 for Phase I awards and $2,500,000 for Phase II awards.

Funding Type





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

November 14, 2022